NCT03386955 - BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BPI-7711 Capsule

Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)

Trial Locations (4)

The First Affiliated Hospital of Suzhou University, Suzhou

Beijing Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Jiangsu Province Hospital, Nanjing